AstraZeneca and Teva settle Nexium dispute with licensing deal
This article was originally published in Scrip
Executive Summary
AstraZeneca has granted Teva Pharmaceutical Industries a licence for it to market a generic version of the gastrointestinal disorder treatment Nexium (esomeprazole magnesium) delayed-release capsules in the US from May 27th, 2014 (or earlier under certain circumstances).